

Third Party Viral Specific T-cells (VSTs)

Status: RECRUITING

Eligibility Criteria

Sex: ALL

Age: 0 month(s) and over

Healthy Volunteers: This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Immunocompromised patient with evidence of viral infection or reactivation
- Age >1 day
- Recipients who have had a stem cell transplant must be at least 21 days after stem cell infusion
- Clinical status must allow tapering of steroids to < 0.5mg/kg prednisone or other steroid equivalent
- Must be able to receive CTL infusion in Cincinnati
- Informed consent obtained by PI or sub-investigator either in person or by phone

Exclusion Criteria:

- Active acute GVHD grades II-IV
- Uncontrolled bacterial or fungal infection
- Uncontrolled relapse of malignancy requiring treatment with chemotherapy
- Infusion of ATG or alemtuzumab within 2 weeks of VST infusion
- Biopsy confirmed acute rejection of solid organ transplant OR empiric treatment of suspected but not confirmed acute rejection of solid organ transplant within the last 30 days

Conditions & Interventions

Interventions:

BIOLOGICAL: Viral Specific VST Infusion

Conditions:

Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host

Keywords:

Epstein-Barr Virus (EBV), Adenovirus (ADV), Cytomegalovirus (CMV), T-Cells, Donor, BK virus (BKV)

More Information

Description:

The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.

Contact(s): Jamie Wilhelm - Jamie.Wilhelm@cchmc.org

Principal Investigator:

Principal Investigator ID:

Phase: PHASE2

IRB Number:

System ID: NCT02532452

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cchmc.org> to find a Study which is right for you and contact clinicalstudies@cchmc.org if you have questions or need assistance.